Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Surely 20p this week with this news is realistic? It works so just a matter of time for a big deals.
Really couldn't care about Transform trial...don't get why so hung up on it...the main focus is US...they've always been clear about that...meanwhile London Clinic and Goodboody distribution deals are undoubtedly good news for UK strategy for those who care about what is a relatively small market in the grand scheme of things..
I completely agree Bat, these hospitals wouldn't risk their reputation by recommending dodgy products. We just need to get some traction on both sales and the share price. Things are definitely looking a lot rosier than a week ago.
More than happy to continue to hold, not brave enough to add more though
…and there will be no stopping this.
We can (justifiably, imho) criticise the management team for over exuberance in 2023, but the tech remains solid and continues to have the potential to be world leading.
Not the announcement we want !!
Transform UK trial where is it??
Well we know it works and companies are coming on board
GLA it’s coming
So many announcements
Latest just adds to their capacity.
Looking good
Goodbody Clinic is a provider of private health tests using a network of over 140 clinics
· Goodbody Clinic will also offer men the option of booking a nurse visit to come to their home for blood collection
Haha dugs positive spin on it, what else we going to do dug? Most I'm hoping for is to recoup as much loss as possible when the time comes, I'm not on any rush for the money so I'll sit tight and await news
Worth reiterating that OBD now has 3 labs, Malaysia, US and UK. At current sales rates they are each presumably processing approximately 1 test per day. Nevertheless the critical role they play in massaging our CEO's ego suggests the overheads are exceptional value for money.
Was swifly removed lol
I see my suggestion to DM
And she will probably get skin beauty treatments for free too
London Clinic funds should help pay the Burrows little princess her weekly loot.
I find a lot of quite bizzare, patented in US, what's that all about? Lab there before here. Literally zero news on any progress stateside.
As I said, what a salesman, had us all buying hand over fist right up to October and 50p at a point, I'm actually glad I traded at that juncture, getting in at 11p and selling at 48p, I bought back in prior to October and been left holding the bag since.
So my guilt for trading absolved
The Labs are quite simply total white elephants and very expensive ones at that, OBD should have waited for demand to justify committed lab space with all the associated overheads and just farmed out the test analysis to others short term to minimise their outgoings fwiw.
Yes Kong, I'm aware of both tests, I'm aware of the previous, I'm aware of the prices there being issued for (overpriced imo) and I'm aware of all the facts, didn't just stumble in off the highstreet and went oh this looks nice!
But we're not talking about the previous are we, we are talking about it's latest, and about the recent labs built here and stateside recent!
And yes I'm also aware of the pitch that these was to fly off the shelves, and that continuing narrative by burrows which was factually incorrect as he barely sold any, as you said 2 a day!
I'm aware of all this, so don't come in with SILLY attitude, telling me I don't UNDERSTAND
Dusty,
To be clear, it's NOT the tests themselves that is the key issue here, it the FACT that despite all the company fanfare they have actually sold FA in any volumes.
Hope that helps
Dustyslay
You need to understand what you’re talking about.
Oxford have 2 tests , one came out 21/2 years ago and one came out last October
As from last RNS telling of sales, if I remember correctly sales from both tests was just over 2 per day
One test is aprox £2,750
And one test is aprox £750
Why is it silly fella? As far as I'm aware it come out last year to much fanfare here, and didn't even have a processing lab up and running, the UK one only up end of march. I get other devices of similar nature have been longer, but if you knew that abd had negative sentiments then why did you invest on this one?
Dustyslay
Asking if it’s too early to be expecting reasonable sales is a little silly.
One of the tests came to the market two and a half years ago.
The board have simply not acted accordingly.
That is why there has been 2 or 3 funding rounds.
And trust me there will be another because the money from last funding round is going very quickly.
The anticipated sales will be too little too late.
They need more money for the large wages of the board
Maybe the results at the end of the month could be a mirror opposite to the fiasco of the last set.
In addition, there seems to be a lot of RNS coming out recently. Seem keen to reverse the downward spiral which is a massive positive. I'm probably getting carried away, could they be trying to talk up the price so they can get a better buyout price???
Teething problems?
I still believe this is one of the best pieces of innovation regarding testing it really just needs traction, are we too early to be expecting the sales?
I believe that's simply down to the board hyping it, if they was realistic, honest and gave it the time it deserves perhaps this mess was avoidable.
But we have both labs up and running in UK and US, we have positives but we need news, results and a real push to market not the we sell tesla, they sell themselves approach
Good to see PSE accessible to at least 27 Urologists who will order all tests available to private patients as the London clinic website is promoting PSE as a more accurate blood test than PSA. A positive step in my opinion.
Good idea demoting him to mktg. Salary 20k per annum and gets extra on results. Should probably mean he will earn around 20k pa
This hit 50p once!!!
Burrows some salesman ill give him that.
Could sell you an empty packet of crisps and have you believe it's of benefit to you, next level selling.
But that's all the credit I'll give him.
We should have him demoted to marketing, we may get somewhere